Legal News

Todd Eury of the Pharmacy Podcast Network is joined by Josh Bolin of the NABP to talk about DSCSA, what benefits it will provide, and how to make sure your pharmacy is ready when it goes into effect this November.

The act is currently set to go into effect in just over three months.

According to a spokesperson, the company is prepared to take the lawsuit to the Supreme Court.

The combination of Lynparza and abiraterone reduced the risk of disease progression or death by 76% vs. abiraterone alone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Iowa's Department of Health and Human Services, which manages the two health insurers that delivered care to adults and children in the state’s Medicaid program last year, was alleged to provide inadequate mental and behavioral health care to children on Medicaid.

The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.

The newly FDA-approved prescription product delivers nalmefene to the nasal cavity to reverse the effects of opioid overdose.

Health plans must continue providing free screenings pending court’s further consideration of case.

The atrial fibrillation drug, asundexian, may provide protection from thrombotic events without a corresponding increase in bleeding risk.

The company that developed the treatment said it will benefit "millions" of patients.

The brand-new treatment from Elanco is currently the only approved therapeutic solution proven to treat canine parvovirus.

Despite having a highly differentiated clinical value proposition compared to branded, twice-nightly oxybates, Avadel is pricing Lumryz at $64.67 per gram or around $177,034 annually, which is on par with twice-nightly oxybate products that require chronic, middle-of-the-night awakening.

Both Democrats and Republicans voted to bring back the act that attempts to improve use of antibiotics

The NexGard COMBO topical solution from Boehringer Ingelheim helps protect cats from tapeworms and other intestinal parasites like fleas, ticks, and heartworms.

STAQ, a 503B outsourcing facility, started making desmopressin nasal spray after Ferring Pharmaceuticals suspended production nearly three years ago.

The FDA is hoping these warnings are a positive step in what will be an extremely long process of ending opioid related deaths.

The Senate Finance Committee recently released a framework for legislation, and the leaders of the “big three” PBMs are scheduled to be witnesses at another committee's hearing regarding insulin prices on May 10.

The expansion from Express Scripts offers increased reimbursement opportunities and creates an Independent Pharmacy Advisory Committee to expand the role of rural, suburban and urban pharmacies in the healthcare system.

RizaFilm is a different formulation of rizatriptan that has been changed into a film, meant to be taken orally and absorbed in mouth.

This comes after a district court in Texas ruled to keep Mifepristone available, but with heavy restrictions.

Proposed legislation would cap the price of insulin at $35 for a 30-day supply.

GrayMatters Health plans to use its technology for other mental health indications in the future.

The FDA granted the EUA based on the phase 3 trial results that demonstrated vilobelimab's efficacy compared to placebo, with a 23.9% relative reduction in all-cause mortality from COVID-19 at 28 days.

The FDA, state governors, and OB/GYN groups around the country are fighting back against Judge Matthew Kacsmaryk’s ruling.

The drug, called Atovaquone, has been voluntarily recalled due to possible Bacillus cereus contamination.

Data suggest confirmatory trials conducted for drugs granted accelerated approval by the FDA have taken over 3 years on average to complete since 2012.

The biopharmaceutical company says it is “extremely disappointed” with the results of the COURAGE-ALS study, which failed to meet primary or secondary endpoints.

Members of the Senate Finance Committee are pushing PBMs to modernize the rules regarding out of pocket costs and competition.

The ruling states that insurers and employers who run plans for employees will have a choice over how- and whether- to cover certain routine screenings, exams and tests.

The drug is a rare FDA-approved liquid formulation that treats ulcers and lowers risk of gastrointestinal bleeding in chronically ill patients.